TrialJournal of hematology & oncology2021

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.

Fulvia Pimpinelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.